Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy
The combination of iPSC-mediated rejuvenation and dual-antigen recognition via CAR and native TCR confers superior cytotoxicity, persistence, and proliferative potential compared to conventional CD19-CAR-T cells. These findings provide a proof-of-concept for a vaccine-synergy strategy in which <i>in vivo</i> TCR restimulation supports selective expansion and sustained antitumor effect of dual-antigen recognition T-cells that can be a promising treatment approach for B-cell malignancies.
Authors
- Midori Ishii (ORCID: https://orcid.org/0000-0001-9597-9458)
- Shintaro Kinoshita (ORCID: https://orcid.org/0009-0004-6268-4433)
- Hajime Yasuda (ORCID: https://orcid.org/0000-0002-2896-7737)
- Miki Ando (ORCID: https://orcid.org/0000-0002-1858-4863)
- Yoshiki Furukawa
- Ayaka Goto
- Norihide Izumi
- Hiromitsu Nakauchi
- Jun Ando
Institutions
- Juntendo University (JP)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Stem Cell Institute (PA)
- Stanford University (US)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-02-26
- DOI
- https://doi.org/10.3389/fcell.2026.1772146
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00